Chinese english Japanese Germany Korea
ChemicalBook > Product Catalog >API >Specialty drugs >Antidote >Deferoxamine

Deferoxamine

Deferoxamine Structure
CAS No.
70-51-9
Chemical Name:
Deferoxamine
Synonyms
DESFEROXAMINE;dfoa;taone;entaone;ba33112;desferin;desferex;desferan;ba-29837;ba-33112
CBNumber:
CB8506290
Molecular Formula:
C25H48N6O8
Molecular Weight:
560.69
MOL File:
70-51-9.mol
Modify Date:
2024/7/2 8:55:37
Request For Quotation

Deferoxamine Properties

Melting point 139°C
Boiling point 627.9°C (rough estimate)
Density 1.2216 (rough estimate)
refractive index 1.5540 (estimate)
pka 9.08±0.50(Predicted)
form Solid
color White to off-white
EPA Substance Registry System Deferoxamine (70-51-9)

SAFETY

Risk and Safety Statements

Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H317
Precautionary statements  P261-P272-P280-P302+P352-P333+P313-P321-P363-P501
Toxicity LD50 oral in mouse: 1340mg/kg

Deferoxamine Chemical Properties,Uses,Production

Description

Deferoxamine was introduced in the 1960s for chelation of iron. It is synthesized by removing a central iron molecule from ferrioxamine B, a compound obtained from the microorganism Streptomyces pilosus. Deferoxamine binds to iron from ferritin and forms ferrioxamine, a very stable and water-soluble chelate with a characteristic reddish color.

Uses

Deferoxamine is used for the treatment of both acute iron intoxication and chronic iron overload due to transfusiondependent anemias. It has also been used in trials for malaria treatment and for aluminum chelation in hemodialysis patients. Studies of a rat model of intracerebral hemorrhage have noted that deferoxamine treatment reduced oxidative stress from iron release, indicating a possible role in preventing damage associated with hemorrhagic strokes.

Environmental Fate

Localized infusion or injection site reactions may occur with deferoxamine administration, such as pain, urticaria and flushing of the skin. Hypersensitivity reactions have been documented with both acute and chronic administration of deferoxamine. Some of the more serious side effects include infusion rate-related hypotension, renal insufficiency, neurotoxicity, growth retardation, pulmonary toxicity, and infections. Deferoxamine may induce venous dilation when given at doses greater than 15 mg kg-1 h-1 leading to poor venous return, depressed cardiac output, and eventually hypotension. Increased levels of histamine have been noted during hypotensive episodes, although pretreatment with antihistamines has not been shown to stop the reaction. An acute decrease in glomerular filtration rate and renal plasma flow secondary to hypotension is the possible mechanism underlying the nephrotoxicity induced by deferoxamine. Depletion of iron, translocation of copper, and chelation of other trace elements including zinc may interfere with critical iron-dependent enzymes, causing oxidative damage within various tissues. These are possible mechanisms thought to be responsible for deferoxamineinduced neurotoxicity, growth retardation, and pulmonary toxicity. In vitro studies have shown that deferoxamine inhibits the synthesis of prostaglandin, hemoglobin, ferritin, collagen, and DNA. The iron–deferoxamine complex, ferrioxamine, is a growth factor for many bacteria and fungi. Deferoxamine has been associated with Yersinia enterocolitica overgrowth and fatal cases of mucormycosis with prolonged therapy.

Deferoxamine Preparation Products And Raw materials

Raw materials

Dicyclohexylcarbodiimide Sodium cyanoborohydride O-Benzylhydroxylamine hydrochloride Succinic anhydride Palladium hydroxide
Acetic anhydride Aluminium-nickel 6-Dimethylaminopurine 4-[(5-{[(benzyloxy)carbonyl]amino}pentyl)(hydroxy)amino]-4-oxobutanoic acid Butanoic acid, 4-[(4-cyanobutyl)(phenylmethoxy)amino]-4-oxo-
benzyl N-[5-(N-hydroxy-3-{[5-(N-hydroxy-3-{[5-(N-hydroxyacetamido)pentyl]carbamoyl}propanamido)pentyl]carbamoyl}propanamido)pentyl]carbamate Butanediamide, N'-[5-[[4-[[5-[acetyl(phenylmethoxy)amino]pentyl]amino]-1,4-dioxobutyl](phenylmethoxy)amino]pentyl]-N-(4-cyanobutyl)-N-(phenylmethoxy)- (9CI) (5-Aminopentyl)(phenylmethoxy)carbamic acid tert-butyl ester benzyl 5-(3,6-dioxomorpholino)pentylcarbamate Benzyl (5-(hydroxyaMino)pentyl)carbaMate
chevron_left

1of3

chevron_right

Preparation Products

Deferoxamine Suppliers

Global( 47)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
Pharmaffiliates Analytics and Synthetics P. Ltd +91-172-5066494 Haryana, India 6773 58 Inquiry
CLEARSYNTH LABS LTD. +91-22-45045900 Hyderabad, India 6351 58 Inquiry
Henan Tianfu Chemical Co.,Ltd. +86-0371-55170693 +86-19937530512 China 21667 55 Inquiry
Shaanxi Dideu Medichem Co. Ltd +86-029-89586680 +86-18192503167 China 8744 58 Inquiry
Dayang Chem (Hangzhou) Co.,Ltd. 571-88938639 +8617705817739 China 52861 58 Inquiry
PT CHEM GROUP LIMITED China 35426 58 Inquiry
GIHI CHEMICALS CO.,LIMITED +8618058761490 China 50000 58 Inquiry
Wuhan Topule Biopharmaceutical Co., Ltd +8618327326525 China 8474 58 Inquiry
Aladdin Scientific +1-+1(833)-552-7181 United States 52927 58 Inquiry
Wuhan Jingkang en Biomedical Technology Co., Ltd +8613720134139 China 5225 58 Inquiry
Supplier Advantage
Pharmaffiliates Analytics and Synthetics P. Ltd 58
CLEARSYNTH LABS LTD. 58
Henan Tianfu Chemical Co.,Ltd. 55
Shaanxi Dideu Medichem Co. Ltd 58
Dayang Chem (Hangzhou) Co.,Ltd. 58
PT CHEM GROUP LIMITED 58
GIHI CHEMICALS CO.,LIMITED 58
Wuhan Topule Biopharmaceutical Co., Ltd 58
Aladdin Scientific 58
Wuhan Jingkang en Biomedical Technology Co., Ltd 58

Related articles

  • Side effects of Deferoxamine
  • Deferoxamine was introduced in the 1960s for chelation of iron. It is synthesized by removing a central iron molecule from fer....
  • Jan 17，2022

70-51-9(Deferoxamine)Related Search:

ALTRENOGEST Glycine Deferiprone DEFEROXAMINE MESYLATE,DEFEROXAMINE METHANESULFONATE SALT,DEFEROXAMINE MESYLATE SALT Aminoferrocene
MAFA Pentobarbital sodium AMINO ACIDS Acetochlor+Atrazine (20%),penetrating emulsion Deferoxamine
Deferoxamine Hydrochloride hydroxyethylstarch-deferoxamine deferoxamine G1 gallium(67)-deferoxamine-dialdehyde starch-fibrinogen conjugate deferoxamine-gamma-folate conjugate
hydroxyethyl starch-deferoxamine conjugate dextran-deferoxamine
chevron_left

1of4

chevron_right
deferoxamideb deferoxamin deferoxamine deferoxamineb deferoxaminum deferrioxamine deferrioxamineb desferan desferex desferin desferral desferriferrioxaminb desferrin desferrioxamineb entaone n-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(n-hydroxy n’-[5-[[4-[[5-(acetylhydroxamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pen n-benzoyl-ferrioxamine n-benzoylferrioxamineb nsc-527604 ButanediaMide,N4-[5-[[4-[[5-(acetylhydroxyaMino)pentyl]aMino]-1,4-dioxobutyl]hydroxyaMino]pentyl]-N1-(5-aMinopentyl)-N1-hydroxy- 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(n-acetylhydroxylamino)-6,11,17, 22-tetraazaheptaeicosane 3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentone,30-amino-3,14,25-trih 3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentone,30-amino-3,14,25-trihyd 30-amino-3,14,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-p 30-amino-3,14,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pen acetamido)pentyl]carbamoyl]propionohydroxamicacid ba-29837 ba33112 ba-33112 butanediamide,n’-(5-((4-((5-(acetylhydroxyamino)pentyl)amino)-1,4-dioxobutyl)h pentyl)-3-((5-(n-hydroxyacetamido)pentyl)carbamoyl)- taone tyl]-n-(5-aminopentyl)-n-hydroxybutanediamide ydroxyamino)pentyl)-n-(5-aminopentyl)-n-hydroxy- N-[5-[[4-[5-azanylpentyl(hydroxy)amino]-4-oxo-butanoyl]amino]pentyl]-N'-[5-[ethanoyl(hydroxy)amino]pentyl]-N-hydroxy-butanediamide N'-[5-[acetyl(hydroxy)amino]pentyl]-N-[5-[[4-[5-aminopentyl(hydroxy)amino]-4-keto-butanoyl]amino]pentyl]-N-hydroxy-succinamide N'-[5-[acetyl(hydroxy)amino]pentyl]-N-[5-[[4-[5-aminopentyl(hydroxy)amino]-4-oxobutanoyl]amino]pentyl]-N-hydroxybutanediamide N1-(5-Aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)-pentyl)amino)-4-oxobuta DESFERROXAMINE N'-[5-[[4-[[5-(Acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxysuccinamide N'-{5-[ACETYL(HYDROXY)AMINO]PENTYL}-N-[5-({4-[(5-AMINOPENTYL)(HYDROXY)AMINO]-4-OXOBUTANOYL}AMINO)PENTYL]-N-HYDROXYSUCCINAMIDE N1-(5-aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)pentyl)amino)-4-oxobutanamido)pentyl)succinamide Deferoxamine USP/EP/BP dfoa DESFEROXAMINE Deferoxamine B|||Desferrioxamine B 70-51-9 C25H48N6O8